Bispecific antibodies with binding sites for both FcRγIII (CD16A) and a tumour-specific epitope act as a specific molecular binder that joins and transports NK cells to the vicinity of tumour cells for target elimination in a manner similar to CARs [548]. This evidence concerns the gene FCGR3A and neoplasm.